Drug interactions: New mechanisms and clinical relevance;Arzneimittelinteraktionen: Neue mechanismen und klinische relevanz

Internist

Volumn 41, Issue 4, 2000, Pages 338-343

  Paneitz, A ^a   Meissner, K ^a   Kroemer, H K ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; CELIPROLOL; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DEXAMETHASONE; DIGOXIN; DIHYDROPYRIDINE DERIVATIVE; DOMPERIDONE; FUROSEMIDE; GENTAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LOPERAMIDE; MEPHENYTOIN; METHADONE; MEVINOLIN; MIBEFRADIL; MIDAZOLAM; MIDAZOLAM MALEATE; MORPHINE; NIFEDIPINE; OMEPRAZOLE; PACLITAXEL; PHENYTOIN; PROPAFENONE; SAQUINAVIR; TALINOLOL; TERFENADINE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

DRUG CROSS REACTIVITY; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME REGULATION; MEMBRANE TRANSPORT; PHARMACODYNAMICS; PHARMACOKINETICS; REVIEW;

EID: 0034054207     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050515     Document Type: Review

References (31)

1. 1. Billups SJ, Carter BL (1998) Mibefradil: a new class of calcium-channel antagonists [see comments]. Ann Pharmacother 32:659-671
2. 2. Borcherding SM, Baciewicz AM, Self TH (1992) Update on rifampin drug interactions. II. Arch Intern Med 152:711-716
3. 3. Borst P (1999) Multidrug resistance: a solvable problem? Ann Oncol 10:162-164
4. 4. Borst P, Schinkel AH, Smit JJ, Wagenaar E, van Deemter L, Smith AJ et al. (1993) Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 60:289-299
5. 5. Cordon-Cardo C, O'Brien JP, Casals D et al. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86:695-698
6. 6. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183-187
7. 7. Evers R, Zaman GJ, van Deemter L et al. (1996) Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 97:1211-1218
8. 8. Fromm MF, Busse D, Kroemer HK, Eichelbaum M (1996) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796-801
9. 9. Fromm MF, Hofmann U, Griese EU, Mikus G (1995) Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. Clin Pharmacol Ther 58:374-382
10. 10. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM (1999) Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552-557
11. 11. Gault H, Longerich L, Dawe M, Fine A (1984) Digoxin-rifampin interaction. Clin Pharmacol Ther 35:750-754
12. 12. Greiner B, Eichelbaum M, Fritz P et al. (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153
13. 13. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162
14. 14. Kim AE, Dintaman JM, Waddell DS, Silverman JA (1998) Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 286:1439-1445
15. 15. Kim RB, Wandel C, Leake B et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16:408-414
16. 16. Lum BL, Gosland MP (1995) MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 9:319-336
17. 17. Matsunga SK, Plezia PM, Karol MD, Katz MD, Camilli AE, Benowitz NL (1989) Effects of passive smoking on theophylline clearance. Clin Pharmacol Ther 46:399-407
18. 18. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. (1990) Torsades de pointes occurring in association with terfenadine use. JAMA 264:2788-2790
19. 19. Mullins ME, Horowitz BZ, Linden DH, Smith GW, Norton RL, Stump J (1998) Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 280:157-158
20. 20. Novi C, Bissoli F, Simonati V, Volpini T, Baroli A, Vignati G (1980) Rifampin and digoxin: possible drug interaction in a dialysis patient [letter]. JAMA 244:2521-2522
21. 21. Obst G (2000) Modulation der MDR-1-vermittelten Chemotherapie-Resistenz bei akuter myeloischer Leukämie. Arzneimitteltherapie 18:12-16
22. 22. Pisarik P (1996) Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Arch Fam Med 5:413-416
23. 23. Prueksaritanont T, Ma B, Tang C et al. (1999) Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Br J Clin Pharmacol 47:291-298
24. 24. Schinkel AH (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8:161-170
25. 25. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524
26. 26. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524
27. 27. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE (1998) Rhabdomyolysis due to interaction of simvastatin with mibefradil [letter]. Lancet 351:1929-1930
28. 28. Spahn-Langguth H, Baktir G, Radschuweit A et al. (1998) P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36:16-24
29. 29. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C (1995) MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36:1-6
30. 30. Vallabhaneni VR (1998) Choroid plexus epithelial expression of MDR1 P-glykoprotein and multidrug resistence-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci 96:3900-3905
31. 31. Welker HA, Wiltshire H, Bullingham R (1998) Clinical pharmacokinetics of mibefradil. Clin Pharmacokinet 35:405-423